Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.
about
Pharmacological interventions for depression in people with traumatic brain injuryA Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorderRapid antidepressant effects: moving right alongReplication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trialA randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depressionTargeting the glutamatergic system to treat major depressive disorder: rationale and progress to dateKetamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacyExtended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled studyCitalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical responseNew therapeutic targets for mood disordersForebrain glutamatergic neurons mediate leptin action on depression-like behaviors and synaptic depressionConvergent animal and human evidence suggests the activin/inhibin pathway to be involved in antidepressant responseAnimal models to improve our understanding and treatment of suicidal behaviorBrain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.Glo1 inhibitors for neuropsychiatric and anti-epileptic drug developmentGlutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.Pharmacogenetics of antidepressant response.A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder.A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.Modeling the dynamics of disease states in depression.Glutamatergic modulators: the future of treating mood disorders?New targets for rapid antidepressant action.Ketamine and the next generation of antidepressants with a rapid onset of actionRating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scalesUse of ketamine in acute cases of suicidalityThe forced swim test as a model of depressive-like behaviorNovel glutamatergic agents for major depressive disorder and bipolar disorder.Therapeutic potential of metabotropic glutamate receptor modulators.Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled studyRelationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.Tracking the impact of translational research in psychiatry: state of the art and perspectives¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolismAgomelatine as monotherapy for major depression: an outpatient, open-label study.The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders.Potential Pathways Involved in the Rapid Antidepressant Effects of Nitrous Oxide.Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks.Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS studySuicidal ideation during antidepressant treatment: do genetic predictors exist?Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?
P2860
Q24200516-51E27E81-2EDA-4EE1-A5C9-FE4F7D48D16FQ24602988-AC007677-C156-41D5-A689-31F0E02F8DB8Q24614410-C411B3F7-BC26-4310-97F7-221E515185C5Q24629398-3BD46420-97B4-4790-B4E1-CE3520FBDEA2Q24630153-C896D6F8-2B38-4887-9346-1ED6E8345165Q27004490-0A56EB44-46A2-41F4-9D1A-017EE647E2B5Q27024227-B15014CA-8939-4B32-8915-AD82F61A8388Q28254377-C22D0550-C98D-4860-932F-EA350BF886F1Q28306033-04D832F4-BE8F-4F6C-B66A-7ABCBC2DD002Q28743068-23CDA02E-9B01-4A80-8090-25485A9641F3Q30508512-59D140B3-ED9E-4412-A477-55E0316C4938Q30534765-6B4E0DDA-E244-4E3B-8DB0-14FC9137B8A8Q33635653-D284882A-60BD-4B6F-85C8-2874461DCA3FQ33643067-5FDA3926-32DA-4FBE-A911-4414A8CF96FEQ33676132-0367BF92-816A-4DA1-BC8F-CDBD539EC96EQ33874459-4CCE1FA3-E310-4A87-A17F-9FC48914F765Q34155796-15060BD4-BEE3-4C6D-91A9-3F6CFBD3B371Q34292341-3E6BDF10-7FE2-49E6-9CAA-AC95533C64B3Q34315128-F796FA3D-A4D0-4777-8765-CC215DBF4E09Q34361887-1F9725C0-9A77-45AF-A942-FCC65776EF05Q34398007-73A72572-3EE4-4319-AAE5-76E9DE3627CEQ34507177-E86FD2A7-B202-4CFD-B477-D98CE5701344Q34978041-B4D73C50-6FA5-43DE-8D2E-9A5038FB4C76Q35019889-4C5F426F-4446-40D0-B9A0-158EC153B941Q35241848-AA405993-C118-4B5A-A0F1-2FB473952ACFQ35458705-6022EFA9-FAE1-4745-B720-22DB5AF6DBB1Q35661119-51C795EE-D094-4CCF-846B-01A341AAF6CAQ35778704-03CBBEDD-9338-4225-AEE5-F4B7940F7964Q35892768-48F6A86E-BD19-4430-88BE-735BDF44F05DQ36233963-76690E0D-6CDC-475F-A416-EC2C890C2407Q36498636-23A3D6C1-5EFE-4EB2-AE99-CFDEFE951784Q36865559-FA1D7239-886D-44CE-A6A0-F535674E5FE5Q37254909-DDD5ED28-0BEB-407B-A0C3-453349F679ACQ37387700-9400802E-6EA6-4DFE-A3B4-1C1CE01DDA30Q37424323-8912C59F-0A52-48A9-B57C-64196308361CQ37442874-027EDC38-D9ED-4BB3-8B4F-40E20DCB86CBQ37686306-C913EED0-53B5-4041-AB81-22959FCFBAB8Q37724201-03209651-27A2-44B6-8F38-5D26BBEDAB2FQ37885976-F7BD80CF-91F1-4C2E-A8A5-4D095C4A7ED0Q37958033-F8656CCD-A3EC-4EB8-9B82-9CCDFF85D992
P2860
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rapid onset of antidepressant ...... of major depressive disorder.
@en
Rapid onset of antidepressant ...... of major depressive disorder.
@nl
type
label
Rapid onset of antidepressant ...... of major depressive disorder.
@en
Rapid onset of antidepressant ...... of major depressive disorder.
@nl
prefLabel
Rapid onset of antidepressant ...... of major depressive disorder.
@en
Rapid onset of antidepressant ...... of major depressive disorder.
@nl
P2093
P2860
P356
P1476
Rapid onset of antidepressant ...... of major depressive disorder.
@en
P2093
Carlos A Zarate
David A Luckenbaugh
Giacomo Salvadore
Husseini K Manji
P2860
P304
P356
10.4088/JCP.V69N0610
P577
2008-06-01T00:00:00Z